JP2005530784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530784A5 JP2005530784A5 JP2004505051A JP2004505051A JP2005530784A5 JP 2005530784 A5 JP2005530784 A5 JP 2005530784A5 JP 2004505051 A JP2004505051 A JP 2004505051A JP 2004505051 A JP2004505051 A JP 2004505051A JP 2005530784 A5 JP2005530784 A5 JP 2005530784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- day
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 102100031939 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 229960002594 arsenic trioxide Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- -1 doxetaxol Chemical compound 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 1
- 229960000435 oblimersen Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38084202P | 2002-05-17 | 2002-05-17 | |
| US42460002P | 2002-11-06 | 2002-11-06 | |
| PCT/US2003/015470 WO2003097052A2 (en) | 2002-05-17 | 2003-05-16 | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006288966A Division JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Division JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Division JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530784A JP2005530784A (ja) | 2005-10-13 |
| JP2005530784A5 true JP2005530784A5 (https=) | 2006-12-14 |
Family
ID=29553516
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505051A Pending JP2005530784A (ja) | 2002-05-17 | 2003-05-16 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2015125342A Expired - Lifetime JP6194335B2 (ja) | 2002-05-17 | 2015-06-23 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2015125342A Expired - Lifetime JP6194335B2 (ja) | 2002-05-17 | 2015-06-23 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Country Status (19)
| Country | Link |
|---|---|
| EP (9) | EP2561874A3 (https=) |
| JP (8) | JP2005530784A (https=) |
| KR (2) | KR100793564B1 (https=) |
| CN (13) | CN102342938B (https=) |
| AT (1) | ATE459357T1 (https=) |
| AU (1) | AU2003234626B2 (https=) |
| CA (10) | CA2752127A1 (https=) |
| CY (3) | CY1110013T1 (https=) |
| DE (1) | DE60331537D1 (https=) |
| DK (1) | DK1505973T3 (https=) |
| ES (2) | ES2521672T3 (https=) |
| IL (9) | IL165254A0 (https=) |
| LU (1) | LU92642I2 (https=) |
| MX (1) | MXPA04011311A (https=) |
| NZ (5) | NZ584663A (https=) |
| PT (2) | PT2105135E (https=) |
| SI (1) | SI1505973T1 (https=) |
| WO (1) | WO2003097052A2 (https=) |
| ZA (3) | ZA200503656B (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| CN102342938B (zh) * | 2002-05-17 | 2014-08-20 | 细胞基因公司 | 用于治疗和控制实体瘤的方法及组合物 |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| AU2003287381B2 (en) * | 2002-10-31 | 2008-03-06 | Celgene Corporation | Composition for the treatment of macular degenration |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2005016326A2 (en) * | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN1867331B (zh) | 2003-09-17 | 2010-05-26 | 美国政府健康及人类服务部 | 作为TNF-α调节剂的沙利度胺类似物 |
| US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20120039065A (ko) * | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| KR20070011379A (ko) | 2004-03-17 | 2007-01-24 | 라스 미카엘 라르센 | 시각 사이클 억제에 의한 망막증의 예방 |
| BRPI0509019A (pt) * | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| EP1744749A4 (en) * | 2004-04-14 | 2009-04-22 | Celgene Corp | METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES |
| CN101098694A (zh) * | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| JP2008520731A (ja) * | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物 |
| SI1928492T1 (sl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo |
| CN101365806B (zh) * | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
| WO2007120669A1 (en) | 2006-04-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| EP2023912A2 (en) * | 2006-05-26 | 2009-02-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds in combination therapy |
| CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| PL2068874T3 (pl) * | 2006-08-07 | 2015-06-30 | Abbvie Biotherapeutics Inc | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1 |
| WO2008057196A2 (en) * | 2006-10-19 | 2008-05-15 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| RU2348420C2 (ru) * | 2007-04-17 | 2009-03-10 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения местно-распространенного рака легкого |
| RU2536242C2 (ru) * | 2007-09-28 | 2014-12-20 | Антродженезис Корпорейшн | Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров |
| UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
| CA2712724A1 (en) * | 2008-01-29 | 2009-08-06 | Celgene Corporation | Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency |
| RU2398525C1 (ru) * | 2009-03-25 | 2010-09-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| WO2011066351A1 (en) * | 2009-11-24 | 2011-06-03 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| NZ607906A (en) * | 2010-08-18 | 2015-11-27 | Theresa Deisher | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| EP2637653B1 (en) * | 2010-11-11 | 2018-01-10 | Ingo Schmidt-Wolf | Compositions comprising ethacrynic acid and lenalidomide and/or thalidomide for use in treating myeloma |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| MX2015003114A (es) * | 2012-09-10 | 2015-07-06 | Celgene Corp | Metodos para el tratamiento de cancer de mama localmente avanzado. |
| CN105246480A (zh) * | 2013-04-02 | 2016-01-13 | 细胞基因公司 | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |
| GB201322626D0 (en) * | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| WO2016116854A1 (en) * | 2015-01-20 | 2016-07-28 | Raghavan Sreevatsan | Self-illuminating cheek retractor |
| JP2018521962A (ja) | 2015-04-30 | 2018-08-09 | ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ | 催奇形性医薬化合物を介した患者処置 |
| EP3313528B1 (en) * | 2015-06-29 | 2021-08-04 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
| KR20180086195A (ko) * | 2015-10-21 | 2018-07-30 | 테크리슨 리미티드 | 면역 매개 암 치료를 위한 조성물 및 방법 |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| EP3490605B1 (en) | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| KR20200078498A (ko) * | 2017-10-26 | 2020-07-01 | 신바이어스 파마 아게 | 레날리도마이드 즉시 방출 제형 |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| WO2020048546A1 (zh) * | 2018-09-07 | 2020-03-12 | 南京明德新药研发有限公司 | 三环取代哌啶二酮类化合物 |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| CN114502176A (zh) * | 2019-10-04 | 2022-05-13 | 达纳-法伯癌症研究所股份有限公司 | 作为zeta链相关蛋白激酶70(zap70)激动剂的免疫调节性酰亚胺药物及其用途 |
| US11666579B2 (en) * | 2019-10-21 | 2023-06-06 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3228601A (en) | 1964-02-20 | 1966-01-11 | Monarch Marking Systems Inc | Controls for marking machine |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| NZ333903A (en) | 1996-07-24 | 2000-02-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| RU2188819C2 (ru) | 1996-08-12 | 2002-09-10 | Селджин Корпорейшн | НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB |
| NZ336035A (en) * | 1996-11-05 | 2002-03-28 | Childrens Medical Center | Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| EP1985285A3 (en) * | 1999-04-01 | 2009-08-12 | Hana Biosciences, Inc. | Compositions and methods for treating lymphoma |
| KR20020082888A (ko) * | 2000-03-17 | 2002-10-31 | 쎌세러퓨틱스,인코포레이티드 | 폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법 |
| BR0110877A (pt) * | 2000-05-15 | 2003-03-11 | Celgene Corp | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CN102342938B (zh) | 2002-05-17 | 2014-08-20 | 细胞基因公司 | 用于治疗和控制实体瘤的方法及组合物 |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
-
2003
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
-
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
-
2006
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
-
2009
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
-
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
-
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
-
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
-
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I2/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
-
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530784A5 (https=) | ||
| JP2006507271A5 (https=) | ||
| IL168061A (en) | 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)- piperidine- 2, 6-dione for use in a medicament for treating and managing myelodysplastic syndromes | |
| JP2020172502A5 (https=) | ||
| CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
| JP2007045839A5 (https=) | ||
| RU2010137395A (ru) | Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2009545600A5 (https=) | ||
| RU2316553C2 (ru) | Производные пиперидина, фармацевтическая композиция на их основе и применение | |
| CA2528784A1 (en) | Hexahydropyridoisoquinolines as dpp-iv inhibitors | |
| FI3651766T3 (fi) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä | |
| HRP20100664T1 (hr) | Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta | |
| JP2017515802A5 (https=) | ||
| JP2001522833A5 (https=) | ||
| EP2698158B1 (en) | Immunomodulation by IAP Inhibitors | |
| JP2005526107A5 (https=) | ||
| JP2004536790A5 (https=) | ||
| JP2004534788A5 (https=) | ||
| EP1345604B1 (en) | Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer | |
| JP2005538184A5 (https=) | ||
| US20080207644A1 (en) | Therapeutic materials and methods | |
| JP2021107447A5 (https=) | ||
| US20210023099A1 (en) | Combination therapy with a bet inhibitor and a proteasome inhibitor | |
| WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time |